AC
AZN icon

Alexandria Capital’s AstraZeneca AZN Stock Holding History

Alexandria Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100
Closed -$7K – 603
2015
Q1 		$7K Buy
+100
New +$6.95K ﹤0.01% 447

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Alexandria Capital's AZN Position: Q2 2015 in Review

Alexandria Capital sold out of AstraZeneca (AZN) in Q2 2015, closing a stake of 100 shares — an estimated $7K sold.

Alexandria Capital first reported a position in AZN in Q1 2015 and held it in 1 quarter. The position peaked at $7K in Q1 2015. 376 funds tracked by Wall St. Rank hold AZN as of Q2 2015.

  • Alexandria Capital reported no remaining AstraZeneca position as of Q2 2015 after selling out during the quarter.
  • Alexandria Capital sold 100 AstraZeneca shares in Q2 2015, an estimated $7K.
  • Alexandria Capital first reported a position in AstraZeneca in Q1 2015 and held it in 1 quarter.
  • Alexandria Capital's AstraZeneca position peaked at $7K in Q1 2015.
  • 376 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2015.

Based on Alexandria Capital's 13F filing for Q2 2015, filed 24 Jul 2015.